Desmopressin
ApprovedDDAVP · 1-desamino-8-D-arginine vasopressin
Desmopressin (DDAVP) is a synthetic vasopressin analog modified to eliminate vasopressor activity while retaining antidiuretic potency. FDA-approved for central diabetes insipidus, nocturnal enuresis (bedwetting), and von Willebrand disease, it achieves selective V2 receptor activation. Research explores its role in cognitive enhancement, where intranasal administration shows effects on memory consolidation.